As the U.S. Food and Drug Administration (FDA) has approved the emergency use of Pfizer's Paxlovid, the entry of oral coronavirus treatments into the market is just around the corner.

On the 22nd (local time), the FDA approved the use of Paxlovid at home for high-risk adults, children over the age of 12, and patients with underlying diseases who are likely to be hospitalized in the event of COVID-19.

According to the results of interim analysis of EPIC-HR, a phase 2/3 clinical trial of Paxlovid, the risk of hospitalization or death decreased by 89% in the patient group who administered the treatment within three days of symptom onset. This is higher than 50% of MSD's Molnupiravir, which p